Defactinib: all 31 studies that test it
Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorNot yet recruitingNCT07743554Phase 2
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingNCT07318324Phase 1
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaRecruitingNCT07126158Phase 2
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingNCT06495125Phase 2
- Avutometinib and Defactinib in Diffuse Gastric CancerRecruitingNCT06487221Phase 2
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingNCT06394804Phase 2
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingNCT06369259Phase 2
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT06072781Phase 3
- A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingNCT06007924Phase 2
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingNCT05636514Phase 1
- Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal MelanomaTerminatedNCT04720417Phase 2Results posted
- Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)Active, not recruitingNCT04439331Phase 2Results posted
- Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaCompletedNCT03727880Phase 2Results posted
- Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsTerminatedNCT02004028Phase 2Results posted
- Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic MalignanciesCompletedNCT01943292Phase 1Results posted
- Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaActive, not recruitingNCT05798507Early Phase 1
- A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerActive, not recruitingNCT05787561Phase 2
- Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingNCT05074810Phase 1/2
- Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaActive, not recruitingNCT04331041Phase 2
- Pembrolizumab + Defactinib In Pleural MesotheliomaWithdrawnNCT04201145Phase 1
- Phase I Trial of Defactinib and VS-6766.Active, not recruitingNCT03875820Phase 1
- Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerTerminatedNCT02943317Phase 1
- A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male SubjectsCompletedNCT02913716Phase 1
- Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)Status unknownNCT02758587Phase 1/2
- Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced CancerCompletedNCT02546531Phase 1
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaTerminatedNCT02372227Phase 1
- Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung CancerCompletedNCT01951690Phase 2
- Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural MesotheliomaTerminatedNCT01870609Phase 2
- Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian CancerCompletedNCT01778803Phase 1
- A Study Of PF-04554878 In Patients With Advanced Non-Hematologic MalignanciesCompletedNCT00787033Phase 1